1,597 results on '"Xu, Rui‐Hua"'
Search Results
2. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
3. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023
4. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
5. Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer
6. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
7. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
8. Immunomodulatory molecules in colorectal cancer liver metastasis
9. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
10. Survival influence of gender on 42,345 patients with gastric cardia adenocarcinoma
11. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
12. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer
13. Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response
14. Publisher Correction: Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer
15. Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer
16. A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors
17. Gastric cancer treatment: recent progress and future perspectives
18. Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future
19. Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy
20. Delayed treatment effect predicting (DTEP) model for guiding immuno-oncology trial designs
21. HIPK3 maintains sensitivity to platinum drugs and prevents disease progression in gastric cancer
22. Tumor iron homeostasis and immune regulation
23. First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
24. Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
25. Extended virtual detector theory including quantum interferences
26. Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome
27. Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc
28. Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma
29. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins
30. IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance
31. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
32. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
33. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study
34. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
35. Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis
36. Retraction Note: Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer
37. Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.
38. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
39. Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.
40. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
41. LncRNA TMPO-AS1 promotes esophageal squamous cell carcinoma progression by forming biomolecular condensates with FUS and p300 to regulate TMPO transcription
42. 3D RoI-aware U-Net for Accurate and Efficient Colorectal Tumor Segmentation
43. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA
44. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
45. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response
46. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
47. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer
48. Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients
49. First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
50. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.